---
layout: default
title: Toremifene
parent: Moderate Evidence (L3-L4)
nav_order: 688
evidence_level: L4
indication_count: 10
---

# Toremifene
{: .fs-9 }

Evidence Level: **L4** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using `superpowers:brainstorming`? — not applicable here (this is a fully-specified content-generation task with an explicit template, not a design/build decision). Proceeding directly per the given report spec.

---

# Toremifene: From Breast Cancer to HIV Infectious Disease

## One-Sentence Summary

Toremifene is a selective estrogen receptor modulator (SERM), with its established use in hormone receptor-positive breast cancer referenced throughout the evidence base (marketed elsewhere as Fareston®). The TxGNN model predicts a possible new application in **HIV infectious disease**, but this is currently supported by only **1 preclinical publication** and **no clinical trials**, and the underlying mechanistic link to HIV itself is not established.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Breast cancer (hormone receptor-positive) — inferred from trial/literature context in this evidence pack; not present as a structured regulatory field |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the information present in this evidence pack, Toremifene belongs to the selective estrogen receptor modulator (SERM) class, and its efficacy in breast cancer treatment is well established across multiple trials referenced elsewhere in this pack. Mechanistically, SERMs act by competitively antagonising the estrogen receptor — a pathway with no established direct role in HIV replication or antiretroviral activity.

The single supporting publication for this prediction (PMID 24520056) demonstrates that estrogen receptor antagonists, including tamoxifen and toremifene, have **anti-cryptococcal** (antifungal) activity in vitro and synergise with fluconazole and amphotericin B. Cryptococcosis is an opportunistic infection associated with advanced HIV/AIDS, but this is an indirect relationship — the study does not show any antiretroviral or anti-HIV mechanism.

The evidence pack's own rationale flags this explicitly: the TxGNN high score likely reflects **knowledge-graph proximity** to AIDS/HIV-related nodes (via the shared opportunistic-infection literature) rather than a genuine pharmacological link to HIV pathophysiology. This should be treated as a hypothesis-generating signal only, not a validated mechanistic rationale.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [24520056](https://pubmed.ncbi.nlm.nih.gov/24520056/) | 2014 | Preclinical (in vitro) | mBio | Estrogen receptor antagonists (tamoxifen, toremifene) show fungicidal activity against *Cryptococcus* and synergise with fluconazole/amphotericin B in vitro — an antifungal, not antiretroviral, mechanism relevant to HIV-associated opportunistic infection |

---

## Australia Market Information

Toremifene is **not currently registered on the ARTG** (Australian Register of Therapeutic Goods). No marketed products or approved indications exist in Australia at this time.

---

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

*(Key warnings, contraindications and drug interaction data for Toremifene are not currently available in this evidence pack — flagged as Blocking (DG001) and High (DG002) data gaps for TFDA/TGA label warnings and mechanism-of-action confirmation respectively.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The only supporting evidence is a single in vitro preclinical study describing an antifungal (not antiretroviral) mechanism relevant to an HIV-associated opportunistic infection, not HIV itself. There are no clinical trials, and the evidence pack's own analysis attributes the high TxGNN score to knowledge-graph proximity rather than a genuine mechanistic link. Toremifene is also not currently marketed in Australia.

**To proceed, the following is needed:**
- Resolution of Blocking data gap DG001 (TFDA/TGA label warnings and contraindications)
- Resolution of High-priority data gap DG002 (confirmed mechanism of action)
- Direct in vitro/in vivo evidence of antiretroviral or HIV-relevant immune activity (not merely anti-opportunistic-infection activity)
- Any clinical or translational data specifically addressing HIV infection, rather than adjacent AIDS-related conditions
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

